ARVN Arvinas, Inc.
Arvinas, Inc. (ARVN) is expected to report earnings on November 3, 2026, before the market open. The consensus earnings estimate is a loss of $0.80 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +7.7% since its last earnings release on August 4, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Arvinas, Inc.
Arvinas Inc. is a biopharmaceutical company for patients suffering from debilitating and life-threatening diseases. It engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Arvinas Inc. is based in CT, United States.
Sector
Healthcare
Industry
Biotechnology